CSL112 (Apolipoprotein A-I) infusions and cardiovascular outcomes in patients with acute myocardial infarction (ApoA-I event reducing in ischemic syndromes II (AEGIS-II) Trial): Primary trial results
Reported from ACC.24
Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.
ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.
Authors
No comments yet!